CroíValve is developing a Best-In-Class minimally invasive solution for severe Tricuspid Regurgitation (TR).
It is a clear unmet clinical need, with a significant impact on mortality, cardiovascular events and quality of life. With a prevalence greater than aortic stenosis in the population over 65 years, TR is the next structural heart opportunity.
Tricuspid Regurgitation poses unique challenges in comparison with Mitral Regurgitation and so needs a solution specifically designed to overcome these challenges.
The CroíValve DUO™ Tricuspid Coaptation Valve System is a novel approach that combines repair and replacement to provide the right solution for the right heart.
